Compelling evidence indicates that heparanase is a viable target for therapy in cancer, inflammation, autoimmunity, fibrosis, diabetes, kidney dysfunction, viral infections, and other diseases, a view widely accepted by researchers in both academia and pharma, and the topic of a dedicated book and multiple reviews [1,2,5,6,7,8,9,10,14,15]. The gene discussed is HPSE; the disease is viral infectious disease.